novel inhibitor targeting FGFR dysregulation. PLoS ONE 2016, 11 (9),
e0162594
4. R. Porta, R. Borea, A. Coelho et al. FGFR a promising druggable target in
cancer: Molecular biology and new drugs. Critical Reviews in
Oncology/Hematology 2017 (113), 256-267
5. T. Helsten, S. Elkin, E. Arthur et al. The FGFR landscape in cancer:
Analysis of 4,853 tumors by next-generation sequencing. Clinical Cancer
Research 2016 (22), 259-267
6. P. McSheehy, F. Bachmann, N. Forster-Gross et al. Derazantinib (DZB): A
dual FGFR/CSF1R-inhibitor active in PDX-models of urothelial cancer.
Molecular Cancer Therapeutics 2019 (18), 12 Supplement, pp. LB-C12
7. M. A. Cannarile, M. Weisser, W. Jacob et al. Colony-stimulating factor 1
receptor (CSF1R) inhibitors in cancer therapy. Journal for ImmunoTherapy
of Cancer 2017, 5:53
8. Y. Zhu, B. L. Knolhoff, M. A. Meyer et al. CSF1/CSF1R Blockade reprograms
tumor-infiltrating macrophages and improves response to T cell checkpoint
immunotherapy in pancreatic cancer models. Cancer Research 2014 (74),
5057-5069
9. E. Peranzoni, J. Lemoine, L. Vimeux et al. Macrophages impede CD8 T cells
from reaching tumor cells and limit the efficacy of anti--PD-1 treatment.
Proceedings of the National Academy of Science of the United States of
America 2018 (115), E4041-E4050
10. V. Mazzaferro, B. F. El-Rayes, M. Droz dit Busset et al. Derazantinib
(ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive
intrahepatic cholangiocarcinoma. British Journal of Cancer 2019 (120),
165-171. ClinicalTrials.gov-Identifier: NCT01752920
11. FIDES-03: ClinicalTrials.gov-Identifier: NCT04604132
Anhang
Pressemitteilung (PDF)
https://www.globenewswire.com/Tracker?data=Gpyflbpji0yIeCQGU5M1iFJAFnzOuM41LZ-MtaAYe5H__f8oIncl5gNi_Vgpm0hIsVdR9t47ab9LwFHihhfDJEusPkK1HqsyyBR-zqZ_2LBYIRGLHvJ9-pE7ASr5xni7ROYcIoxy52r1xurw7oteQZ5KvrkB0FcSJtIppK8EPz_w7jVdaxAE0Rx885mrfsec
(END) Dow Jones Newswires
February 12, 2021 01:15 ET (06:15 GMT)